Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedure

Phase 3

Completed

Brief Summary: BS-1053 A Prospective Randomized Multi-Centered Safety and Efficacy Evaluation of the Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedures

Detailed Description: This is a multi-centered, randomized trial in patients receiving lung biopsies. Patients will be randomized to either receive or not receive a Bio-Seal Biopsy Track Plug after a lung biopsy per standard hospital protocol. This study is designed to demonstrate safety and efficacy of the Bio-Seal Biopsy Track Plug in reducing pneumothorax rates post lung biopsy.

Recruitment & Eligibility

Inclusion Criteria

The patient must meet all medical conditions for lung biopsy;
The patient must be at least 18 years of age;
The patient, or legal representative, must understand and provide written consent for the procedure;
The patient has a non-calcified, radiologically suspicious opacity or lung nodule, including a metastatic lung module, or mass of at least 1.0 cm in size; as determined by CT scan equipped with measurement software. Suspicious nodules observed by CT scan are defined as non-calcified masses with convex borders, not known to be stable. Suspicious nodules can also be defined as masses demonstrating opacity on chest x-ray that are suspicious by radiographic or clinical means and require biopsy.

Exclusion Criteria

Patients with radiological findings of bullous emphysema located in the area of the anticipated biopsy and biopsy needle track;
Patients who cannot tolerate mild sedation, possibly secondary to poor respiratory status;
Female patients who are pregnant. Note: patients of childbearing potential must have a serum or urine pregnancy test no more than one week prior to the biopsy procedure, and be instructed not to have unprotected sexual intercourse after the test until the biopsy procedure is completed.
Patients who are uncooperative or cannot follow instructions.
Patients who are currently enrolled in another IDE or IND clinical investigation that has not completed the required follow-up period.

Arm && Interventions

Group	Intervention	Description
Bio-Seal Group	Bio-Seal Plug	Bio-Seal Plug Implanted

Primary Outcome Measures

Name	Time	Method
Incidence Rate of Treatment Success	30 days	Treatment success was defined as the absence of a pneumothorax at each of the three follow-up time periods (0-60 minutes, 24 hours and 30 days).

Secondary Outcome Measures

Name	Time	Method
Incidence of Chest Tube Placement	30 days	A chest tube is the definitive initial treatment of a pneumothorax.
Time to Ambulation	30 days
Incidence of Hospital Admissions for Pneumothorax	30 day
Incidence of Adverse Events Related to the Procedure and Device Effects	30 Day	Anticipated, device-related adverse events that were defined in the original protocol.
Number of Participants With Additional Chest X-rays Needed	30 day
Participants Discharged Beyond Hospital's Standard of Care	30-day	Current standard of care for hospital discharge varies. Some institutions allow the patient to be discharged after a 3 hour wait. Others allow discharge after an x-ray indicates no pneumothorax. Since this study was randomized with control patients, the time to discharge beyond the hospital's standard of care was recorded to see if a trend for later discharge was apparent. This measure indicates the number of participants who were discharged later than their hospital's standard of care.
Incidence of Adverse Events	30 days	Any treatment emergent adverse events (not considered device related by the investigators).

Locations (18): Rhode Island Hospital
🇺🇸
Providence, Rhode Island, United States
Stanford University Medical Center
🇺🇸
Stanford, California, United States
Florida Research Network
🇺🇸
Gainesville, Florida, United States
UMass Memorial Medical Center
🇺🇸
Worcester, Massachusetts, United States
St. Josephs Radiology Limited
🇺🇸
Tuscon, Arizona, United States
Memorial Medical Center
🇺🇸
Johnstown, Pennsylvania, United States
UCLA School of Medicine
🇺🇸
Los Angeles, California, United States
Scottsdale Medical Imaging
🇺🇸
Scottsdale, Arizona, United States
Vascular and Interventional Radiology
🇺🇸
New Haven, Connecticut, United States
Univerisity of California, San Diego
🇺🇸
San Diego, California, United States
Univeristy of Cincinnati Medical Center
🇺🇸
Cincinnati, Ohio, United States
University of Texas/MD Anderson Cancer Center
🇺🇸
Houston, Texas, United States
Morton Plant Mease Health Care
🇺🇸
Clearwater, Florida, United States
St Lukes Hospital
🇺🇸
Bethlehem, Pennsylvania, United States
Sacred Heart Medical Center & Heart Institute of Spokane
🇺🇸
Spokane, Washington, United States
St. Louis Medical Center
🇺🇸
St. Louis, Missouri, United States
Baptist Memorial Hospital
🇺🇸
Memphis, Tennessee, United States
Evergreen Healthcare Diagnostic Imaging
🇺🇸
Kirkland, Washington, United States